



Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer, inflammatory and metabolic diseases:

- **OncoMimics:** highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). E Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is about to enter development for indolent non-Hodgkin B-cell lymphomas.
- **EndoMimics:** a new generation of biologics targeting inflammatory diseases (EM101) and metabolic such as Type 2 diabetes.

These pipelines have been created using Enterome's highly efficient proprietary drug discovery platform machine learning and lab assays to interrogate and decode the world's largest database of gut bacterial unique source of novel precision drugs.

In addition, Enterome's clinical candidate Sibofimloc (also referred to as TAK-018) is advancing through clinical trials in Crohn's disease. Sibofimloc has been partnered with Takeda globally, with Enterome receiving significant profit share in the US.

Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.



#### ENTEROME

94/96 avenue Ledru-Rollin  
75011 PARIS, FRANCE  
Tel : +33 (0)1 75 77 27 85  
Email : [info@enterome.com](mailto:info@enterome.com)

#### INFORMATIONS

RCS Paris N° 508 580 289  
Siret : 50858028900025  
NAF : 7211Z  
N° TVA : FR40 508 580 289